Which is better, IKS.BO or PME.AX?

On the Buffett-Fit framework, Pro Medicus Limited (PME.AX) currently grades higher than IKS.BO — 78/100 (B grade) vs 68/100 (B). That said, "better" depends on which framework you trust — IKS.BO wins on none; PME.AX wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy IKS.BO or PME.AX?

This page is an educational comparison, not investment advice. Both IKS.BO and PME.AX are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is IKS.BO better than PME.AX for value investing?

On the Buffett-style value-investing framework, PME.AX currently grades higher — 78/100 vs 68/100, a 10-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between IKS.BO and PME.AX on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). IKS.BO currently scores 68/100 (B grade); PME.AX scores 78/100 (B grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, IKS.BO or PME.AX?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. IKS.BO and PME.AX are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, IKS.BO or PME.AX?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are IKS.BO and PME.AX both Healthcare stocks?

Yes — both INVENTURUS KNOWLEDGE SOLUTIONS (IKS.BO) and Pro Medicus Limited (PME.AX) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this IKS.BO vs PME.AX comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

INVENTURUS KNOWLEDGE SOLUTIONS

IKS.BO$299.01BHealthcare Market cap, Sector

Pro Medicus Limited

PME.AX$16.79BHealthcare Market cap, Sector

Overall winner

Pro Medicus Limited

IKS.BO 07 PME.AX

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

Fit scores by strategy

IKS.BO0wins

7winsPME.AX

Warren Buffett

68C

B78

Benjamin Graham

79B

A90

Philip Fisher

79B

A98

Peter Lynch

73B

A100

Joel Greenblatt

63C

B84

Charlie Munger

75B

A91

Terry Smith

71B

A96

Side-by-side metrics

Metric	IKS.BO	PME.AX
Market cap	Winner: $299.01B	$16.79B
P/E (TTM)	Winner: 38.3x	147.6x
EV/EBIT	Winner: 28.7x	106.8x
ROIC (TTM)	20.59%	42.56% Winner
Gross margin	49.0%	99.85% Winner
Net margin	22.59%	54.12% Winner
Revenue CAGR 5y	Winner: 45.76%	31.61%
EPS CAGR 5y	33.43%	37.34% Winner
Debt / Equity	0.3x	0.0x Winner
Dividend yield	-	-

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

IKS.BO leads on

Market cap$299.01Bvs $16.79B+94%
P/E (TTM)38.3xvs 147.6x+74%
EV/EBIT28.7xvs 106.8x+73%
Revenue CAGR 5y45.76%vs 31.61%+31%

PME.AX leads on

Debt / Equity0.0xvs 0.3x+97%
Net margin54.12%vs 22.59%+58%
ROIC (TTM)42.56%vs 20.59%+52%
Gross margin99.85%vs 49.0%+51%

More like IKS.BO

IKS.BO vs JSLL.NS IKS.BO vs JSLL.BO IKS.BO vs 4728.TWO IKS.BO vs SANOFICONR.NS

More like PME.AX

PME.AX vs JSLL.NS PME.AX vs JSLL.BO PME.AX vs 4728.TWO PME.AX vs SANOFICONR.NS

Read the full Buffett-Brain analysis for IKS.BO Read the full Buffett-Brain analysis for PME.AX

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Side-by-side metrics

Metric	IKS.BO	PME.AX
Market cap	Winner: $299.01B	$16.79B
P/E (TTM)	Winner: 38.3x	147.6x
EV/EBIT	Winner: 28.7x	106.8x
ROIC (TTM)	20.59%	42.56% Winner
Gross margin	49.0%	99.85% Winner
Net margin	22.59%	54.12% Winner
Revenue CAGR 5y	Winner: 45.76%	31.61%
EPS CAGR 5y	33.43%	37.34% Winner
Debt / Equity	0.3x	0.0x Winner
Dividend yield	-	-

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

IKS.BO leads on

Market cap$299.01Bvs $16.79B+94%
P/E (TTM)38.3xvs 147.6x+74%
EV/EBIT28.7xvs 106.8x+73%
Revenue CAGR 5y45.76%vs 31.61%+31%

PME.AX leads on

Debt / Equity0.0xvs 0.3x+97%
Net margin54.12%vs 22.59%+58%
ROIC (TTM)42.56%vs 20.59%+52%
Gross margin99.85%vs 49.0%+51%